Hi Reader,

When I began seriously researching tinnitus during my own journey many years ago, this line of research was already being talked about as “the most promising thing coming.” Back then, it sounded close.

Now, in 2026, I want to share a clear, grounded update based on what was actually said in a recent interview released during Tinnitus Awareness Week.

I want to share this without hype and without false hope.

🧠 What this device actually is

This is a bimodal neuromodulation device, meaning it combines sound stimulation with gentle electrical stimulation to the head or neck.

Some of you may already be familiar with Neuromod Devices’ Lenire, which has been available in some markets for a few years and also uses a form of bimodal stimulation.

This new device is similar in category, but different in origin and approach.

The stimulation timing used here was developed directly from decades of neuroscience research into how tinnitus-related activity emerges in the brain, particularly in a brainstem region involved in auditory and somatosensory integration. The protocol was not chosen by trial and error. It was derived from laboratory findings and then carried into human studies.

That research driven timing and targeting is what the developers emphasized as the key distinction.

🧍 Who this device was originally designed for

This research originally focused on somatosensory (somatic) tinnitus, meaning tinnitus that can change with jaw movement, neck tension, posture, or facial movement.

That said, the human clinical studies included people with tinnitus more broadly, not only classic somatic cases. So while the roots are somatic, the treatment is being positioned as a tinnitus therapy in general.

📊 What the studies showed so far

Two controlled human studies were discussed, one in 2018 and a longer follow up study in 2023.

In those studies:

• Participants used the device daily for 4 to 6 weeks
• Many experienced a gradual reduction in tinnitus loudness
• Tinnitus Functional Index scores improved
• About 60 percent showed clinically meaningful improvement
• Improvements continued even after treatment stopped in the longer study

Importantly, these were placebo controlled trials, which matters a lot in tinnitus research.

⚠️ What this device does not do

This was stated clearly in the interview.

This device is not designed to treat hyperacusis. It specifically targets tinnitus related brain activity, not sound sensitivity.

🩺 How access would work, if approved

If and when this device becomes available:

• Initial access would likely be through audiologists or ENT doctors
• It would be prescribed for home use
• Direct to consumer access was mentioned only as a possible future pathway, not an initial plan

⏳ The hardest part, timing

No launch date was given. No approval timeline was shared. No near term availability was hinted at.

The only time related comment came near the end of the interview, when the CEO was asked:
“Five years from today, where would you like to be?”

His answer was that he hopes the device will be available in major markets like the US and Europe by then.

That was clearly framed as an aspiration, not a release plan.

Reading this carefully, it suggests that availability is still years away, and very unlikely in 2026 or even 2027.

I know that is disappointing. At the same time, it also suggests the team is trying to do this the hard, rigorous way, without shortcuts or overpromising.

ℹ️ Bottom line

This is one of the most scientifically grounded tinnitus treatment efforts we have seen in a long time.

The research is real. The results are promising. But the path to availability is slow, careful, and measured.

I will continue tracking real milestones and will share updates when something concrete changes.

If you are feeling both hopeful and frustrated about tinnitus research, that reaction makes complete sense.

You are not alone in it.

Warmly, Guy.
​